CPG
ACAD icon

Cornerstone Planning Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Cornerstone Planning Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$649 Buy
+26
New +$572 ﹤0.01% 1617
2024
Q2 		– Sell
-50
Closed -$853 – 1260
2024
Q1 		$853 Buy
+50
New +$1.24K ﹤0.01% 812

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cornerstone Planning Group's ACAD Position: Q2 2026 in Review

Cornerstone Planning Group opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 26 shares worth $649. The stake represents ﹤0.01% of the portfolio and ranks #1617 among its holdings. This is a return to the name: Cornerstone Planning Group previously reported a position in ACAD as recently as Q1 2024.

Cornerstone Planning Group first reported a position in ACAD in Q1 2024 and has held it in 2 quarters since. The position peaked at $853 in Q1 2024. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cornerstone Planning Group held 26 shares of Acadia Pharmaceuticals worth $649 as of Q2 2026.
  • Acadia Pharmaceuticals was a new Cornerstone Planning Group position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1617 holding.
  • Cornerstone Planning Group first reported a position in Acadia Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • Cornerstone Planning Group's Acadia Pharmaceuticals position peaked at $853 in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.